Company profile
Karyopharm Therapeutics Inc.
Pipeline4 assets
- SelinexorKPT-330 / XPOVIO / XPO1 (Exportin 1) / Small Molecule / OncologyMultiple MyelomaMarketedActiveUSGlobalEndometrial CancerPhase 3ActiveUSGlobalMyelofibrosisPhase 3ActiveUSGlobal
- EltanexorKPT-8602 / XPO1 (Exportin 1) / Small Molecule / OncologyMyelodysplastic NeoplasmsPhase 2PausedUSColorectal CancerPhase 2PausedUSProstate CancerPhase 2PausedUS
- KPT-9274KPT-9274 / PAK4 / NAMPT / Small Molecule / OncologySolid Tumors & LymphomaPhase 1PausedUS
- VerdinexorKPT-335 / XPO1 (Exportin 1) / Small Molecule / Veterinary Oncology / Infectious DiseasesCanine LymphomaMarketedActiveUS
Latest news9 items
All newsKaryopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
Enrollment • Phase 3Enrollment completion Thu, May 14, 2026
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
Presentation / Abstract • Phase 3